ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy
Principal Investigator
Peter J. DolmanOverview
Study Start/End
Feb 4, 2021Name/Title
Aleksandra Kuzmanovic, Research CoordinatorPhone
604-875-4253Email Address
Aleksandra.Kuzmanovic@vch.caPurpose of Study
The purpose of this study is to assess the efficacy and safety/tolerability of three dose regiments of RVT-1401 in the treatment of active, moderate to severe Graves' Ophthalmopathy.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.